GHRP-6 — Research Reference

GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide and one of the earliest members of the GHRP class to be investigated in research. It acts as an agonist at the growth hormone secretagogue receptor type 1a (GHS-R1a), stimulating pulsatile GH release from the anterior pituitary. GHRP-6 is notable for its pronounced appetite-stimulating effect — more pronounced than any other GHRP at equivalent doses — and for reported gastroprotective properties that have been investigated independently of its GH-releasing activity.

Quick Reference

Overview

GHRP-6 was among the first synthetic peptide growth hormone secretagogues to be characterised in research, with investigations beginning in the early 1980s by Bowers and colleagues. These early studies established the foundational pharmacology of the GHRP class — demonstrating that synthetic hexapeptides could stimulate GH release via a receptor pathway distinct from GHRH. The receptor responsible, later identified as GHS-R1a (the ghrelin receptor), became the basis for subsequent development of Ipamorelin, GHRP-2, Hexarelin, and eventually the endogenous ghrelin itself.

GHRP-6 binds GHS-R1a with high affinity and activates Gαq/11 signalling, triggering phospholipase C-mediated IP3/DAG cascade, intracellular calcium release, and GH exocytosis from somatotrophs. This mechanism is complementary to the GHRH receptor pathway, enabling synergistic GH release when GHRP-6 is combined with a GHRH analogue.

The compound’s gastroprotective properties — investigated in models of gastric ulcer, NSAID-induced GI damage, and surgical anastomosis healing — represent a distinct research area that parallels, though is separate from, similar investigations of BPC-157.

Reported Protocols

Subcutaneous Administration

Subcutaneous injection is the most commonly reported route in research accounts. Commonly reported doses range from 100 mcg to 300 mcg per injection, administered 1–3 times daily.

• Standard protocol: 100–200 mcg per injection, administered on waking, pre-workout, and/or before sleep. The pre-sleep injection is commonly reported to capitalise on the overlap with the nocturnal GH pulse.
• Fasted state: Administration in a fasted state is commonly reported. Food intake — particularly carbohydrates — elevates insulin and blunts the GH response to GHS-R1a stimulation. GHRP-6’s pronounced appetite stimulation makes the timing of injection relative to meals a practical consideration distinct from other GHRPs.
• Appetite management: Because GHRP-6 produces strong appetite stimulation 30–60 minutes post-injection, some research accounts describe planning the injection immediately before a scheduled meal, using the appetite stimulation as an eating cue rather than a problem to avoid.

Combination With GHRH Analogues

As with other GHRPs, GHRP-6 is frequently reported in combination with GHRH analogues (CJC-1295, Sermorelin) for synergistic GH release. The combination approach is among the most commonly described GH axis research stacks.

Reported Effects

Growth Hormone Release

Research has investigated GHRP-6 for its potential role in stimulating pulsatile GH release from the anterior pituitary via GHS-R1a agonism. Human studies have confirmed significant GH elevation following GHRP-6 administration, with synergistic amplification when combined with GHRH analogues. The GH response is broadly similar in magnitude to GHRP-2 at equivalent doses.

Appetite Stimulation

Research has investigated GHRP-6 for its pronounced appetite-stimulating effect via the ghrelin pathway. GHS-R1a activation in the hypothalamus and vagal nerve terminals stimulates hunger signalling, consistent with ghrelin’s endogenous role as a hunger hormone. GHRP-6’s appetite stimulation is more pronounced than any other GHRP and is reported at doses used for GH research. This effect is simultaneously documented in anecdotal accounts as both a potential research benefit (for researchers seeking increased caloric intake alongside GH stimulation) and a commonly reported side effect.

Gastric Motility and Gastroprotection

Research has investigated GHRP-6 for its potential role in gastric motility stimulation and gastroprotective effects, mediated through peripheral ghrelin receptor activation in the gastrointestinal system. Preclinical studies have investigated GHRP-6 for its potential role in gastric ulcer healing and protection against NSAID-induced gastric damage — a research area that has also been explored for BPC-157 and other GI-active peptides.

IGF-1 Elevation and Body Composition

Research has investigated GHRP-6 for its downstream effects on IGF-1 and body composition via GH-mediated pathways. Anecdotal research accounts describe lean mass support and adipose reduction with prolonged use, consistent with the effects of GH axis stimulation.

Cortisol and Prolactin Elevation

In common with GHRP-2, GHRP-6 produces cortisol and prolactin elevation alongside GH release. These off-target hormonal effects are dose-dependent and transient, distinguishing GHRP-6 from the more selective Ipamorelin.

Reported Side Effects

Reported side effects in research and anecdotal accounts include the following.

Appetite as both effect and side effect: GHRP-6’s pronounced appetite stimulation is consistently described in research and anecdotal accounts as both a potential utility (where increased caloric intake is a research goal) and a significant side effect (for research contexts where appetite control is important). The hunger typically peaks 30–60 minutes post-injection and diminishes within a few hours.

Storage & Handling

Lyophilized Powder (Unreconstituted)

• Refrigerator (2–8°C): Preferred; reported stable for 12 months or more
• Room temperature: Short-term stability acceptable; refrigerator strongly preferred
• Freezer: Acceptable for long-term storage; avoid repeated freeze-thaw cycles
• Protect from light and moisture

Reconstituted Solution

• Refrigerator (2–8°C): Use within 4–6 weeks of reconstitution
• Do not freeze reconstituted GHRP-6
• Bacteriostatic water is the preferred diluent for multi-dose vials
• Discard if the solution becomes cloudy or shows particulate matter

See the Reconstitution Guide for step-by-step instructions.

Frequently Asked Questions

How does GHRP-6 compare to Ipamorelin? Both are GHRPs that act at GHS-R1a. Ipamorelin is highly selective, producing GH release with minimal cortisol, prolactin, or ACTH elevation, and minimal appetite stimulation. GHRP-6 produces strong GH release alongside significant appetite stimulation, cortisol elevation, and prolactin elevation. Ipamorelin is generally preferred for research contexts where hormonal selectivity and appetite management are priorities; GHRP-6 may be selected where appetite stimulation and maximal GH pulse amplitude are research objectives.

How does GHRP-6 compare to GHRP-2? Both produce comparable GH pulses and similar cortisol and prolactin elevation at equivalent doses. The primary distinction is appetite stimulation: GHRP-6 produces substantially more pronounced appetite stimulation than GHRP-2. Anecdotal accounts describe GHRP-6’s hunger effect as intense enough to be disruptive at higher doses. GHRP-2 is generally preferred when appetite stimulation is not a desired outcome.

Why does GHRP-6 cause hunger? GHRP-6 acts at the ghrelin receptor (GHS-R1a), which is the endogenous ghrelin receptor. Ghrelin is the primary endogenous “hunger hormone” — produced by the stomach in a fasted state to signal hunger to the hypothalamus. GHRP-6’s activation of GHS-R1a in both the pituitary (GH release) and hypothalamus (hunger signalling) produces simultaneous GH release and appetite stimulation through the same receptor.

Does GHRP-6 have gastroprotective properties? Research has investigated GHRP-6 for potential gastroprotective effects via peripheral ghrelin receptor activation in the gastrointestinal system, with preclinical studies reporting protective effects in gastric ulcer and NSAID-induced GI damage models. This research area is analogous to but separate from similar investigations of BPC-157.

Related Pages

Goals: Muscle Growth · Performance

Class: GHRPs — Growth Hormone Releasing Peptides

References & Further Reading

• Bowers CY, et al. (1984). On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology, 114(5), 1537–1545. PubMed →
• Howard AD, et al. (1996). A receptor in pituitary and hypothalamus that functions in growth hormone release. Science, 273(5277), 974–977. PubMed →
• Laferrère B, et al. (2005). Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. Journal of Clinical Endocrinology & Metabolism, 90(2), 611–614. PubMed →
• Pombo M, et al. (1995). Interaction of growth hormone (GH)-releasing hormone and GH-releasing peptide-6 in stimulating GH release in children and adults. Hormone Research, 44(4), 166–171. PubMed →